Antibiotics currently play little part in the treatment of Buruli ulcer.

Buruli ulcer is often diagnosed late, when treatment can be very difficult and frustrating.

This followed a stay in Zaire to study the Buruli ulcer.

Buruli ulcer has been reported from at least 32 countries around the world, mostly in tropical areas:

The mode of transmission of Buruli ulcer is not entirely known.

Buruli ulcer commonly affects poor people in remote rural areas with limited access to health care.

Mycolactone appears to play a key role in the pathogenesis of Buruli ulcer.

After tuberculosis and leprosy, Buruli ulcer is the third most common mycobacteriosis of humans.

Unlike Buruli ulcer, tropical ulcers are very painful.

In humans, mycolactone is the toxin responsible for Buruli ulcers, doing so by damaging tissues and inhibiting the immune response.

A series of epidemiological studies show the existence of seasonal variation in the appearance of Buruli ulcer cases.

The diagnosis of Buruli ulcer is usually based on the characteristic appearance of the ulcer in an endemic area.

He is particularly well known for his work with Hansen's disease (Leprosy), Buruli ulcer, and filarial diseases.

However, as small compensation, his may be the first recorded case and first description of Mycobacterium ulcerans infection (Buruli ulcer).

HIV infection does not seem to predispose to Buruli ulcer but may facilitate dissemination of M. ulcerans.

Various molecular methods for fingerprinting of M. ulcerans are now being developed to facilitate studies on the epidemiology of Buruli ulcer.

Sitafloxacin (INN; also called DU-6859a) is a fluoroquinolone antibiotic that shows promise in the treatment of Buruli ulcer.

In vivo studies using a guinea pig model of infection suggest that mycolactone is responsible for both the extensive tissue damage and immunosuppression which accompanies Buruli ulcer.

Buruli ulcer: BCG may protect against or delay the onset of Buruli ulcer.

In addition to Leprosy, Dr Meyers encounterd many other diseases including some which would later become part of his great life work, Buruli Ulcer and Streptocerciasis.

Buruli ulcer disease was identified in 1897 by Sir Albert Cook, a British physician, at Mengo Hospital in Kampala, Uganda.

In the Ivory Coast, where Buruli ulcer is endemic, the water bugs are present in swamps and rivers, where human activities such as farming, fishing, and bathing take place.

His main areas of research are clinical pharmacology, pharmacogenetics, infectious diseases such as malaria, schistosomiasis, Buruli ulcer, and HIV/AIDS and public sector pharmaceutical management.

Buruli ulcer is currently endemic in the Benin, Côte d'Ivoire, Ghana, Guinea, Liberia, Nigeria, Sierra Leone and Togo.

A mycobacterial skin disease occurring primarily in children under 15 years old has prompted the Buruli Ulcer program, which provides education on the treatment of the ulcers that result from the skin disease.